Anabolic effects of intermittent PTH on osteoblasts

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 127-134

  Greenfield, Edward M ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anabolic; Immediate early genes; Osteoblast; Osteoprotegerin; PTH; RANKL; Sclerostin; Transcription factors

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; AMPHIREGULIN; CONTINUOUS PARATHYROID HORMONE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; INTERMITTENT PARATHYROID HORMONE; JAGGED1; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN P21; SCLEROSTIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT4 PROTEIN;

ARTICLE; DOWN REGULATION; DRUG MECHANISM; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84861728776     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020127     Document Type: Article

References (126)

1. Tam, C.S.; Heersche, J.N.M.; Murray, T.M.; Parsons, J.A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology, 1982, 110, 506-512.
2. Dempster, D.W.; Cosman, F.; Parisien, M.; Shen, V.; Lindsay, R. Anabolic actions of parathyroid hormone on bone. Endocr. Rev., 1993, 14, 690-709.
3. Dobnig, H.; Turner, R.T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology, 1997, 138(11), 4607-4612.
4. Frolik, C.; Black, E.; Cain, R.; Satterwhite, J.; Brown-Augsburger, P.; Sato, M.; Hock, J. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone, 2003, 33, 372-379.
5. Partridge, N.C.; Bloch, S.R.; Pearman, A.T. Signal transduction pathways mediating parathyroid hormone regulation of osteoblastic gene expression. J. Cell. Biochem., 1994, 55, 321-327.
6. Qin, L.; Raggatt, L.J.; Partridge, N.C. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol. Metab., 2004, 15(2), 60-65.
7. Jilka, R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone, 2007, 40(6), 1434-1446.
8. Kousteni, S.; Bilezikian, J. Cellular actions of parathyroid hormone. In: Principles of Bone Biology; 3rd ed.; Bilezikian, J.; Raisz, L.; Martin, T., Eds.; Elsevier: Amsterdam, 2008; Vol. 1, pp. 639-656.
9. Bisello, A.; Friedman, P. PTH and PTHrP actions on kidney and bone. In: Principles of Bone Biology; Bilezikian, J., Raisz, L., Martin, T., Eds.; Elsevier: Amsterdam, 2008; Vol. 1, pp. 665-712.
10. Gardella, T.; Juppner, H.; Bringhurst, F.; Potts, J. Receptors for parathyroid hormone (PTH) and PTH-relatd protein. In: Principles of Bone Biology, Bilezikian; J.; Raisz, L.; Martin, T., Eds.; Elsevier: Amersdam, 2008; Vol. 1, pp. 555-576.
11. Wittelsberger, A.; Rosenblatt, M. Parathyroid hormone-receptor interactions. In: Principles of Bone Biology, 3rd ed.; Bilezikian, J., Raisz, L., MArtin, T., Eds.; Elsevier: Amsterdam, 2008; Vol. 1, pp. 595-637.
12. Hanley, D.; Watson, P.; Hodsman, A.; Depster, D. Pharmacological mechanisms of therapeutics: parathyroid hormone. In: Principles of Bone Biology; 3rd ed.; Bilezikian, J., Raisz, L., Martin, T., Eds.; Elsevier: Amsterdam, 2008; Vol. 1.
13. Hodsman, A.B.; Fraher, L.J.; Ostbye, T.; Adachi, J.D.; Steer, B.M. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest., 1993, 91(3), 1138-1148.
14. Schmidt, I.U.; Dobnig, H.; Turner, R.T. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology, 1995, 136(11), 5127-5134.
15. Nishida, S.; Yamaguchi, A.; Tanizawa, T.; Endo, N.; Mashiba, T.; Uchiyama, Y.; Suda, T.; Yoshiki, S.; Takahashi, H. E., Increased bone formation by intermittent parathyroid hormone administration is due to stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone, 1994, 15, 717-723.
16. Kostenuik, P.J.; Halloran, B.P.; Turner, R.T.; Morey-Holton, E.R.; Bikle, D.D. Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I. J. Bone Miner. Res., 1999, 14, 21-31.
17. Dobnig, H.; Turner, R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rates by activation of bone lining cells. Endocrinology, 1995, 136, 3632-3638.
18. Rickard, D.J.; Wang, F.L.; Rodriguez-Rojas, A.M.; Wu, Z.; Trice, W.J.; Hoffman, S.J.; Votta, B.; Stroup, G.B.; Kumar, S.; Nuttall, M.E. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone, 2006, 39(6), 1361-1372.
19. Kulkarni, N.; Wei, T.; Kumar, A.; Dow, E.; Stewart, T.; Shou, J.; N'cho, M.; Sterchi, D.; Gitter, B.; Higgs, R.; Halladay, D.; Engler, T.; Martin, T.; Bryant, H.; Ma, Y.; Onyia, J. Changes in Osteoblast, Chondrocyte, and Adipocyte Lineages Mediate the Bone Anabolic Actions of PTH and Small Molecule GSK-3 Inhibitor. J. Cell. Biochem., 2007, 102, 1504-1518.
20. Jilka, R.L.; Weinstein, R.S.; Bellido, T.; Roberson, P.; Parfitt, A.M.; Manolagas, S. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest., 1999, 104(4), 439-446.
21. Chen, H.L.; Demiralp, B.; Schneider, A.; Koh, A.J.; Silve, C.; Wang, C.Y.; McCauley, L.K. Parathyroid hormone and parathyroid hormone-related protein exert both pro-and anti-apoptotic effects in mesenchymal cells. J. Biol. Chem., 2002, 277(22), 19374-19381.
22. Bellido, T.; Ali, A.; Plotkin, L.; Fu, Q.; Gubrij, I.; Roberson, P.; Weinstein, R.; O'Brien, C.; Manolagas, S.; Jilka, R. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced antiapoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J. Biol. Chem., 2003, 278(50), 50259-50272.
23. Sowa, H.; Kaji, H.; Iu, M.F.; Tsukamoto, T.; Sugimoto, T.; Chihara, K. Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts. J. Biol. Chem., 2003, 278(52), 52240-52252.
24. Stanislaus, D.; Yang, X.; Liang, J.; Wolfe, J.; Cain, R.; Onyia, J.; Falla, N.; Marder, P.; Bidwell, J.; Queener, S.; Hock, J. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment. Bone, 2000, 27, 209-218.
25. Hock, J.; Krishnan, V.; Onyia, J.; Bidwell, J.; Milas, J.; Stanislaus, D. Osteoblast apoptosis and bone turnover. J. Bone Miner. Res., 2001, 16, 975-984.
26. Wang, Y.H.; Liu, Y.; Rowe, D.W. Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am. J. Physiol. Endocrinol. Metab., 2007, 292(2), E594-E603.
27. Jilka, R.L.; O'Brien, C.A.; Ali, A.A.; Roberson, P.K.; Weinstein, R.S.; Manolagas, S.C. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone, 2009, 44(2), 275-286.
28. Neer, R.M.; Arnaud, C.D.; Zanchetta, J.R.; Prince, R.; Gaich, G.A.; Reginster, J.Y.; Hodsman, A.B.; Eriksen, E.F.; Ish-Shalom, S.; Genant, H.K.; Wang, O.; Mitlak, B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 2001, 344(19), 1434-1441.
29. Black, D.M.; Greenspan, S.L.; Ensrud, K.E.; Palermo, L.; McGowan, J.A.; Lang, T.F.; Garnero, P.; Bouxsein, M.L.; Bilezikian, J.P.; Rosen, C.J. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med., 2003, 349(13), 1207-1215.
30. Finkelstein, J.S.; Hayes, A.; Hunzelman, J.L.; Wyland, J.J.; Lee, H.; Neer, R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med., 2003, 349(13), 1216-1226.
31. Greenspan, S.L.; Bone, H.G.; Ettinger, M.P.; Hanley, D.A.; Lindsay, R.; Zanchetta, J.R.; Blosch, C.M.; Mathisen, A.L.; Morris, S.A.; Marriott, T.B. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med., 2007, 146(5), 326-339.
32. Orwoll, E.S.; Scheele, W.H.; Paul, S.; Adami, S.; Syversen, U.; Diez-Perez, A.; Kaufman, J.M.; Clancy, A.D.; Gaich, G.A. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res., 2003, 18(1), 9-17.
33. Sellmeyer, D.E.; Black, D.M.; Palermo, L.; Greenspan, S.; Ensrud, K.; Bilezikian, J.; Rosen, C.J. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos. Int., 2007, 18(7), 973-979.
34. Carter, P.H.; Schipani, E. The roles of parathyroid hormone and calcitonin in bone remodeling: prospects for novel therapeutics. Endocr. Metab. Immune Disord. Drug Targets, 2006, 6(1), 59-76.
35. Karsdal, M.A.; Martin, T.J.; Bollerslev, J.; Christiansen, C.; Henriksen, K. Are nonresorbing osteoclasts sources of bone anabolic activity? J. Bone Miner. Res., 2007, 22(4), 487-494.
36. McClung, M.R.; Lewiecki, E.M.; Cohen, S.B.; Bolognese, M.A.; Woodson, G.C.; Moffett, A.H.; Peacock, M.; Miller, P.D.; Lederman, S.N.; Chesnut, C.H.; Lain, D.; Kivitz, A.J.; Holloway, D.L.; Zhang, C.; Peterson, M.C.; Bekker, P.J. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med., 2006, 354(8), 821-831.
37. Delmas, P.D.; Vergnaud, P.; Arlot, M.E.; Pastoureau, P.; Meunier, P.J.; Nilssen, M.H. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone, 1995, 16(6), 603-610.
38. Ma, Y.L.; Zeng, Q.; Donley, D.W.; Ste-Marie, L.G.; Gallagher, J.C.; Dalsky, G.P.; Marcus, R.; Eriksen, E.F. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J. Bone Miner. Res., 2006, 21(6), 855-864.
39. Karsdal, M.A.; Neutzsky-Wulff, A.V.; Dziegiel, M.H.; Christiansen, C.; Henriksen, K. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem. Biophys. Res. Commun., 2008, 366(2), 483-488.
40. rd ed.; Bilezikian, J., Raisz, L., Martin, T., Eds.; Elsevier: Amsterdam, 2008; Vol. 1, pp. 221-236.
41. Yamane, H.; Sakai, A.; Mori, T.; Tanaka, S.; Moridera, K.; Nakamura, T. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone, 2009, 44(6), 1055-1062.
42. Lindsay, R.; Nieves, J.; Formica, C.; Henneman, E.; Woelfert, L.; Shen, V.; Dempster, D.; Cosman, F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet,1997, 350(9077), 550-555.
43. Cosman, F.; Nieves, J.; Woelfert, L.; Formica, C.; Gordon, S.; Shen, V.; Lindsay, R. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res., 2001, 16(5), 925-931.
44. Fogelman, I.; Fordham, J.N.; Fraser, W.D.; Spector, T.D.; Christiansen, C.; Morris, S.A.; Fox, J. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcif. Tissue Int., 2008, 83(2), 85-92.
45. Deal, C.; Omizo, M.; Schwartz, E.N.; Eriksen, E.F.; Cantor, P.; Wang, J.; Glass, E.V.; Myers, S.L.; Krege, J.H. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebocontrolled trial. J. Bone Miner. Res., 2005, 20(11), 1905-1911.
46. Cosman, F.; Nieves, J.W.; Zion, M.; Barbuto, N.; Lindsay, R. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos. Int., 2008, 19(4), 529-535.
47. Li, X.; Liu, H.; Qin, L.; Tamasi, J.; Bergenstock, M.; Shapses, S.; Feyen, J.H.; Notterman, D.A.; Partridge, N.C. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J. Biol. Chem., 2007, 282(45), 33086-33097.
48. Greenfield, E.M.; Shaw, S.M.; Gornik, S.A.; Banks, M.A. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J. Clin. Invest., 1995, 96, 1238-1244.
49. Gesty-Palmer, D.; Flannery, P.; Yuan, L.; Corsino, L.; Spurney, R.; Lefkowitz, R.J.; Luttrell, L.M. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci. Transl. Med., 2009, 1(1), 1ra1.
50. Onyia, J.; Helvering, L.; Gelbert, L.; Wei, T.; Huang, S.; Chen, P.; Dow, E.; Maran, A.; Zhang, M.; Lotinun, S.; Lin, X.; Halladay, D.; Miles, R.; Kulkarni, N.; Ambrose, E.; Ma, Y.; Frolik, C.; Sato, M.; Bryant, H.; Turner, R. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J. Cell. Biochem., 2005, 15, 403-418.
51. Greenfield, E.M.; Gornik, S.A.; Horowitz, M.C.; Donahue, H.J.; Shaw, S.M. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J. Bone Miner. Res.,1993, 8, 1163-1171.
52. Pollock, J.H.; Blaha, M.J.; Gornik, S.A.; Stevenson, S.; Greenfield, E.M. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J. Bone Miner. Res., 1996, 11, 754-759.
53. Greenfield, E.M.; Horowitz, M.C.; Lavish, S.A. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J. Biol. Chem., 1996, 271, 10984-10989.
54. Dai, J.C.; He, P.; Chen, X.; Greenfield, E.M. TNF]and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone, 2006, 38, 509-520.
55. Chen, X.; Dai, J.C.; Greenfield, E.M. Termination of immediateearly gene expression after stimulation by parathyroid hormone or isoproterenol. Am. J. Physiol. Cell Physiol., 2002, 283, C1432-C1440.
56. Chen, X.; Dai, J.C.; Orellana, S.A.; Greenfield, E.M. Endogenous protein kinase inhibitorppterminates immediate-early gene expression induced by cAMP-dependent protein kinase (PKA) signaling: Termination depends on PKA inactivation rather than PKA export from the nucleus. J. Biol. Chem., 2005, 280, 2700-2707.
57. Chen, X.; Song, I.; Dennis, J.; Greenfield, E. Endogenous PKI terminates the anti-apoptotic effect of parathyroid hormone and t-adrenergic agonists. J. Bone Miner. Res., 2007, 22, 656-664.
58. Krishnan, V.; Moore, T.L.; Ma, Y.L.; Helvering, L.M.; Frolik, C.A.; Valasek, K.M.; Ducy, P.; Geiser, A.G. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol. Endocrinol., 2003, 17 (3), 423-435.
59. Selvamurugan, N.; Pulumati, M.R.; Tyson, D.R.; Partridge, N.C. Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor alpha1. J. Biol. Chem., 2000, 275 (7), 5037-5042.
60. Tintut, Y.; Parhami, F.; Le, V.; Karsenty, G.; Demer, L.L. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasomedependent regulation. J. Biol. Chem., 1999, 274(41), 28875-28879.
61. Yang, X.; Matsuda, K.; Bialek, P.; Jacquot, S.; Masuoka, H.C.; Schinke, T.; Li, L.; Brancorsini, S.; Sassone-Corsi, P.; Townes, T.M.; Hanauer, A.; Karsenty, G. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell, 2004, 117(3), 387-398.
62. Yu, S.; Franceschi, R.T.; Luo, M.; Zhang, X.; Jiang, D.; Lai, Y.; Jiang, Y.; Zhang, J.; Xiao, G. Parathyroid hormone increases activating transcription factor 4 expression and activity in osteoblasts: requirement for osteocalcin gene expression. Endocrinology, 2008, 149(4), 1960-1968.
63. Yu, S.; Franceschi, R.T.; Luo, M.; Fan, J.; Jiang, D.; Cao, H.; Kwon, T.G.; Lai, Y.; Zhang, J.; Patrene, K.; Hankenson, K.; Roodman, G.D.; Xiao, G. Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. PLoS One, 2009, 4(10), e7583.
64. Kramer, I.; Keller, H.; Leupin, O.; Kneissel, M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol. Metab., 2010, 21(4), 237-244.
65. Bellido, T.; Ali, A.A.; Gubrij, I.; Plotkin, L.I.; Fu, Q.; O'Brien, C.A.; Manolagas, S.C.; Jilka, R.L. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology, 2005, 146(11), 4577-4583.
66. Keller, H.; Kneissel, M. SOST is a target gene for PTH in bone. Bone, 2005, 37(2), 148-158.
67. Silvestrini, G.; Ballanti, P.; Leopizzi, M.; Sebastiani, M.; Berni, S.; Di Vito, M.; Bonucci, E. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J. Mol. Histol., 2007, 38(4), 261-269.
68. O'Brien, C.A.; Plotkin, L.I.; Galli, C.; Goellner, J.J.; Gortazar, A.R.; Allen, M.R.; Robling, A.G.; Bouxsein, M.; Schipani, E.; Turner, C.H.; Jilka, R.L.; Weinstein, R.S.; Manolagas, S.C.; Bellido, T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One, 2008, 3(8), e2942.
69. Kramer, I.; Loots, G.G.; Studer, A.; Keller, H.; Kneissel, M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Miner. Res., 2010, 25(2), 178-189.
70. Locklin, R.; Khosla, S.; Turner, R.; Riggs, B. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J. Cell. Biochem., 2003, 89, 180-190.
71. Lee, S.K.; Lorenzo, J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology, 1999, 140, 3552-3561.
72. Ma, Y.L.; Cain, R.L.; Halladay, D.L.; Yang, X.; Zeng, Q.; Miles, R.R.; Chandrasekhar, S.; Martin, T.J.; Onyia, J.E. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 2001, 142, 4047-4054.
73. Fu, Q.; Jilka, R.; Manolagas, S.; O'Brien, C. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem., 2002, 277, 48868-48875.
74. Clohisy, J.C.; Scott, D.K.; Brakenhoff, K.D.; Quinn, C.O.; Partridge, N.C. Parathyroid hormone induces c-fos and c-jun messenger RNA in rat osteoblastic cells. Mol. Endocrinol., 1992, 6, 1834-1842.
75. Lee, K.; Deeds, J.D.; Chiba, S.; Un-No, M.; Bond, A.T.; Segre, G.V. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology, 1994, 134, 441-450.
76. Onyia, J.E.; Bidwell, J.; Herring, J.; Hulman, J.; Hock, J.M. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone, 1995, 17, 479-484.
77. Stanislaus, D.; Devanarayan, V.; Hock, J.M. In vivo comparison of activated protein-1 gene activation in response to human parathyroid hormone (hPTH)(1-34) and hPTH(1-84) in the distal femur metaphyses of young mice. Bone, 2000, 27, 819-826.
78. Demiralp, B.; Chen, H.L.; Koh, A.J.; Keller, E.T.; McCauley, L.K. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology, 2002, 143(10), 4038-4047.
79. Koh, A.; Demiralp, B.; Neiva, K.; Hooten, J.; Nohutcu, R.; Shim, H.; Datta, N.; Taichman, R.; LK, L. M. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology, 2005, 146, 4584-4596.
80. Luiz de Freitas, P.H.; Li, M.; Ninomiya, T.; Nakamura, M.; Ubaidus, S.; Oda, K.; Udagawa, N.; Maeda, T.; Takagi, R.; Amizuka, N. Intermittent PTH administration stimulates preosteoblastic proliferation without leading to enhanced bone formation in osteoclast-less c-fos(-/-) mice. J. Bone Miner. Res., 2009, 24(9), 1586-1597.
81. Koe, R.; Clohisy, J.; Tyson, D.; Pulumati, M.; Cook, T.; Partridge, N. Parathyroid hormone versus phorbol ester stimulation of activator protein-1 gene family members in rat osteosarcoma cells. Calcif. Tissue Int., 1997, 61, 52-58.
82. Sabatakos, G.; Sims, N.; Chen, J.; Aoki, K.; Kelz, M.; Amling, M.; Bouali, Y.; Mukhopadhyay, K.; Ford, K.; Nestler, E.; Baron, R. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat. Med., 2000, 6, 985-990.
83. Jochum, W.; David, J.; Elliott, C.; Wutz, A.; Plenk, H.; Matsuo, K.; Wagner, E. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med., 2000, 6, 980-984.
84. McCauley, L.; Koh-Paige, A.; Chen, H.; Chen, C.; Ontiveros, C.; Irwin, R.; McCabe, L. Parathyroid Hormone Stimulates fra-2 Expression in Osteoblastic Cells in vitro and in vivo. Endocrinology, 2001, 142, 1975-1981.
85. McCabe, L.; Banerjee, C.; Kundu, R.; Harrison, R.; Dobner, P.; Stein, J.; Lian, J.; Stein, G. Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation. Endocrinology, 1996, 137, 4398-4408.
86. Datta, N.; Chen, C.; Berry, J.; McCauley, L. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J. Bone Miner. Res., 2005, 20, 1051-1064.
87. Tetradis, S.; Bezouglaia, O.; Tsingotjidou, A. Parathyroid hormone induces expression of the nuclear orphan receptor Nurr1 in bone cells. Endocrinology, 2001, 142, 663-670.
88. Pirih, F.; Aghaloo, T.; Bezouglaia, O.; Nervina, J.; Tetradis, S. Parathyroid hormone induces the NR4A family of nuclear orphan receptors in vivo. Biochem. Biophys. Res. Commun., 2005, 332, 494-503.
89. Pirih, F.; Tang, A.; Ozkurt, I.; Nervina, J.; Tetradis, S. Nuclear orphan receptor Nurr1 directly transactivates the osteocalcin gene in osteoblasts. J. Biol. Chem., 2004, 279, 53167-53174.
90. Davies, M.; Harding, C.; Raines, S.; Tolley, K.; Parker, A.; Downey-Jones, M.; Needham, M. Nurr1 dependent regulation of pro-inflammatory mediators in immortalised synovial fibroblasts. J. Inflamm,. 2005, 2, 15.
91. Nervina, J.; Magyar, C.; Pirih, F.; Tetradis, S., PGC-1alpha is induced by parathyroid hormone and coactivates Nurr1-mediated promoter activity in osteoblasts. Bone, 2006, 39, 1018-1025.
92. Qin, L.; Tamasi, J.; Raggatt, L.; Li, X.; Feyen, J.; Lee, D.; Dicicco-Bloom, E.; Partridge, N., Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation. J. Biol. Chem., 2005, 280, 3974-3981.
93. Hurley, M.; Tetradis, S.; Huang, Y.; Hock, J.; Kream, B.; Raisz, L.; Sabbieti, M., Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. J. Bone Miner. Res., 1999, 14, 776-783.
94. Hurley, M.M.; Okada, Y.; Xiao, L.; Tanaka, Y.; Ito, M.; Okimoto, N.; Nakamura, T.; Rosen, C.J.; Doetschman, T.; Coffin, J.D. Impaired bone anabolic response to parathyroid hormone in Fgf2-/-and Fgf2+/-mice. Biochem. Biophys. Res. Comm., 2006, 341, 989-994.
95. Sabbieti, M.G.; Agas, D.; Xiao, L.; Marchetti, L.; Coffin, J.D.; Doetschman, T.; Hurley, M.M. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J. Cell. Physiol., 2009, 219(1), 143-151.
96. McCarthy, T.L.; Centrella, M.; Canalis, E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology, 1989, 124, 1247-1253.
97. Canalis, E.; Centrella, M.; Burch, W.; McCarthy, T.L. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone. J. Clin. Invest., 1989, 83, 60-65.
98. Ishizuya, T.; Yokose, S.; Hori, M.; Noda, T.; Suda, T.; Yoshiki, S.; Yamaguchi, A. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest., 1997, 99, 2961-2970.
99. Miyakoshi, N.; Kasukawa, Y.; Linkhart, T.A.; Baylink, D.J.; Mohan, S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology, 2001, 142, 4349-4356.
100. Bikle, D.D.; Sakata, T.; Leary, C.; Elalieh, H.; Ginzinger, D.; Rosen, C.J.; Beamer, W.; Majumdar, S.; Halloran, B.P. Insulin like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J. Bone Miner. Res., 2002, 17, 1570-1579.
101. Wang, Y.; Nishida, S.; Boudignon, B.M.; Burghardt, A.; Elalieh, H.Z.; Hamilton, M.M.; Majumdar, S.; Halloran, B.P.; Clemens, T.L.; Bikle, D.D. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J. Bone Miner. Res., 2007, 22(9), 1329-1337.
102. Franchimont, N.; Wertz, S.; Malaise, M. Interleukin-6: An osteotropic factor influencing bone formation? Bone, 2005, 37(5), 601-606.
103. Elias, J.A.; Tang, W.; Horowitz, M.C. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology, 1995, 136, 489-498.
104. Takeuchi, Y.; Watanabe, S.; Ishii, G.; Takeda, S.; Nakayama, K.; Fukumoto, S.; Kaneta, Y.; Inoue, D.; Matsumoto, T.; Harigaya, K.; Fujita, T. Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J. Biol. Chem., 2002, 277, 49011-49018.
105. Gimble, J.M.; Wanker, F.; Wang, C.S.; Bass, H.; Wu, X.; Kelly, K.; Yancopoulos, G.D.; Hill, M.R. Regulation of bone marrow stromal cell differentiation by cytokines whose receptors share the gp130 protein. J. Cell. Biochem., 1994, 54, 122-133.
106. Raggatt, L.J.; Qin, L.; Tamasi, J.; Jefcoat, S. C. Jr.; Shimizu, E.; Selvamurugan, N.; Liew, F.Y.; Bevelock, L.; Feyen, J.H.; Partridge, N.C. Interleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actions. J. Biol. Chem., 2008, 283(11), 6790-6798.
107. Qin, L.; Qiu, P.; Wang, L.; Li, X.; Swarthout, J.; Soteropoulos, P.; Tolias, P.; Partridge, N., Gene Expression Profiles and Transcription Factors Involved in Parathyroid Hormone Signaling in Osteoblasts Revealed by Microarray and Bioinformatics. J. Biol. Chem., 2003, 278, 19723-19731.
108. Weber, J.; Forsythe, S.; Christianson, C.; Frisch, B.; Gigliotti, B.; Jordan, C.; Milner, L.; Guzman, M.; Calvi, L. Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone, 2006, 39, 485-493.
109. Tezuka, K.; Yasuda, M.; Watanabe, N.; Morimura, N.; Kuroda, K.; Miyatani, S.; Hozumi, N. Stimulation of osteoblastic cell differentiation by Notch. J. BoneMiner. Res., 2002, 17, 231-239.
110. Nobta, M.; Tsukazaki, T.; Shibata, Y.; Xin, C.; Moriishi, T.; Sakano, S.; Shindo, H.; Yamaguchi, A., Critical Regulation of Bone Morphogenetic Protein-induced Osteoblastic Differentiation by Delta1/Jagged1-activated Notch1 Signaling. J. Biol. Chem., 2005, 280, 15842-15848.
111. Cornish, J.; Callon, K.; King, A.; Edgar, S.; Reid, I. The effect of leukemia inhibitory factor on bone in vivo. Endocrinology, 1993, 132, 1359-1366.
112. Cornish, J.; Callon, K.; Edgar, S.; Reid, I. Leukemia inhibitory factor is mitogenic to osteoblasts. Bone, 1997, 21, 243-247.
113. Malaval, L.; Aubin, J. Biphasic effects of leukemia inhibitory factor on osteoblastic differentiation. J. Cell. Biochem. Suppl., 2001, (Suppl. 36), 63-70.
114. Walsh, C.A.; Bowler, W.B.; Bilbe, G.; Fraser, W.D.; Gallagher, J.A. Effects of PTH on PTHrP gene expression in human osteoblasts: up-regulation with the kinetics of an immediate early gene. Biochem. Biophys. Res. Commun., 1997, 239, 155-159.
115. Miao, D.; Li, J.; Xue, Y.; Su, H.; Karaplis, A.; Goltzman, D. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology, 2004, 145, 3554-3562.
116. Horwitz, M.; Tedesco, M.; Gundberg, C.; Garcia-Ocana, A.; Stewart, A. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab., 2003, 88, 569-575.
117. Miao, D.; He, B.; Jiang, Y.; Kobayashi, T.; Soroceanu, M.; Zhao, J.; Su, H.; Tong, X.; Amizuka, N.; Gupta, A.; Genant, H.; Kronenberg, H.; Goltzman, D.; Karaplis, A. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Invest., 2005, 115, 2402-2411.
118. Chen, X.; Stewart, S.; Roberson, P.; Wynne, R.; Manolagas, S.; Jilka, R. Gene expression patterns in response to daily injection of PTH to mice. J. Bone Miner. Res., 2006, 21(Suppl. 1), 322-323.
119. Gaur, T.; Lengner, C.; Hovhannisyan, H.; Bhat, R.; Bodine, P.; Komm, B.; Javed, A.; vanWijnen, A.; Stein, J.; Stein, G.; Lian, J. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem., 2005, 280, 33132-33140.
120. Yamashita, J.; Datta, N.S.; Chun, Y.H.; Yang, D.Y.; Carey, A.A.; Kreider, J.M.; Goldstein, S.A.; McCauley, L.K. Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone. J. Bone Miner. Res., 2008, 23(5), 621-632.
121. Nagase, Y.; Iwasawa, M.; Akiyama, T.; Ogata, N.; Kadono, Y.; Nakamura, M.; Oshima, Y.; Yasui, T.; Matsumoto, T.; Masuda, H.; Bouillet, P.; Nakamura, K.; Tanaka, S. Antiapoptotic molecule Bcl-2 is essential for the anabolic activity of parathyroid hormone in bone. Ann. NY Acad. Sci., 2010, 1192(1), 330-337.
122. Qin, L.; Li, X.; Ko, J.; Partridge, N. Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J. Biol. Chem., 2005, 280, 3104-3111.
123. Aghaloo, T.; Pirih, F.; Shi, A.; Bezouglaia, O.; Tetradis, S. Parathyroid hormone induces mitogen-activated kinase phosphatase 1 in murine osteoblasts primarily through cAMPprotein kinase A signaling. J. Periodontol., 2006, 77, 21-30.
124. Tetradis, S.; Pilbeam, C.; Liu, Y.; Kream, B. Parathyroid hormone induces prostaglandin G/H synthase-2 expression by a cyclic adenosine 3',5'-monophosphate-mediated pathway in the murine osteoblastic cell line MC3T3-E1. Endocrinology, 1996, 137, 5435-5440.
125. Xu, M.; Choudhary, S.; Voznesensky, O.; Gao, Q.; Adams, D.; Diaz-Doran, V.; Wu, Q.; Goltzman, D.; Raisz, L.G.; Pilbeam, C.C. Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice. Bone, 2010, 47(2), 341-352.
126. Zhang, X.; Schwarz, E.; Young, D.; Puzas, J.; Rosie, R.; O'Keefe, R. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest., 2002, 109, 1405-1415.